srch

09.11.2021 · Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile,...

... -- Collaboration accelerates and expands global development of Blueprint Medicines' next-generation EGFR inhibitors with plans to bring ...

Blueprint Medicines reported promising data from a preclinical study of a drug to target three of the most common resistance mutations in ...

Sep 17, 2020 · Based on these preclinical proof-of-concept data, Blueprint Medicines plans to develop BLU-945 as a monotherapy and in combination with other agents for the treatment of patients with osimertinib-resistant EGFR NSCLC. The company plans to initiate an international Phase 1 dose-escalation trial of BLU-945 in the first half of 2021.

Blueprint Medicines' ability to make a success of LNG-451, a preclinical EGFR exon 20 inhibitor it obtained yesterday via its $250m purchase ...

17.09.2020 · Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease.

Preclinical data show LNG-451 potently inhibits all common EGFR exon 20 ... About Blueprint Medicines' EGFR Development Program Derived from ...

Zai Lab will have exclusive rights to commercialize Blueprint's BLU-945 and BLU-701 in EGFR-mutated NSCLC in greater China.

1 dag siden · Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile,...

Adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to Blueprint Medicines' lung ...

1Blueprint Medicines Corporation, Cambridge, Massachusetts, USA BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC Background • BLU-701 activity was tested in biochemical assays for EGFR mutants and WT EGFR

About Blueprint Medicines'EGFR Development Program Derived from Blueprint Medicines'proprietary research platform, BLU-945 and BLU-701 are investigational next-generation EGFR non-covalent tyrosine kinase inhibitors.

Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 ... a compound that targets tumours with EGFR exon 20 mutations.

1Blueprint Medicines Corporation, Cambridge, Massachusetts, USA BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC Background • BLU-701 activity was tested in biochemical assays for EGFR mutants and WT EGFR

1 day ago · Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile,...

Blueprint Medicines, a Massachusetts-based biotech specializing in ... of a protein called EGFR, which, in turn, can help spur tumor growth.

Nov 09, 2021 · -- Collaboration accelerates and expands global development of Blueprint Medicines’ next-generation EGFR inhibitors with plans to bring clinical trials of BLU-945 and BLU-701 to Greater China---- Blueprint Medicines to receive $25 million upfront payment, up to $590 million in potential future milestone payments, and royalties --